Anavex Life Sciences Corp (AVXL)

[georgejjl]

Anavex 2-73 and/or Anavex 3-71 as a treatment for tardive dyskinesia and tardive akathisia

Tardive dyskinesia affects an estimated 500,000 persons in the United States. About 60% to 70% of cases are mild, and about 3% are extremely severe. Particularly at risk are patients who have been treated for schizophrenia, schizoaffective disorder, or bipolar disorder.

Tardive dyskinesia (TD) occurs in 20–25% of patients with long-term antipsychotic therapy. Abnormalities in glutamatergic transmission are considered one of the key components of the pathogenesis of drug-induced side effects. Glutamate acts as excitotoxin under certain conditions and in excessive concentrations.

Benefical Effects of Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia and Tardive Akathisia in Patients with Schizophrenia: Report of Three Cases

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902161/

Good luck and GOD bless,